Novartis: FDA Approves Kesimpta for Multiple Sclerosis

Novartis said the US Food and Drug Administration has approved Kesimpta for the treatment of relapsing forms of multiple sclerosis in adults

• Includes clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease
• Kesimpta (ofatumumab, formerly OMB157) is a targeted, precisely dosed and delivered B-cell therapy
• Has shown superior efficacy with a similar safety profile compared with teriflunomide
• A first-choice treatment option for RMS patients
• First B-cell therapy that can be self-administered once monthly via the Sensoready autoinjector pen
• Kesimpta is expected to be available in the U.S. in early September
• In separate statement, Genmab says Kesimpta is being developed ...